A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia
Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C.
The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a person's blood. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.
Inclusion Criteria:
-Has either not received lipid-lowering therapy (LLT) or has not received certain LLTs within a specified time period prior to the study.
Exclusion Criteria:
Phoenix, Arizona 85020, United States
Albuquerque, New Mexico 87106-4725, United States
Norman, Oklahoma 73069, United States
Yardley, Pennsylvania 19067, United States
San Antonio, Texas 78258, United States
CABA, Buenos Aires C1407GTL, Argentina
Mar del Plata, Buenos Aires B7600FZO, Argentina
Rosario, Santa Fe Province S2000CVD, Argentina
CABA, C1425AGC, Argentina
Fortaleza, Ceará 60430-350, Brazil
Bragança Paulista, São Paulo 12916-542, Brazil
São José do Rio Preto, São Paulo 15090-000, Brazil
North York, Ontario M6B 3H7, Canada
Debrecen, 4032, Hungary
Nelson, Tasman District 7011, New Zealand
Nawton, Waikato Region 3200, New Zealand
Sıhhiye, Ankara 06230, Turkey (Türkiye)
Istanbul, 34080, Turkey (Türkiye)